CA3174699A1 - Ginsenoside compositions - Google Patents

Ginsenoside compositions

Info

Publication number
CA3174699A1
CA3174699A1 CA3174699A CA3174699A CA3174699A1 CA 3174699 A1 CA3174699 A1 CA 3174699A1 CA 3174699 A CA3174699 A CA 3174699A CA 3174699 A CA3174699 A CA 3174699A CA 3174699 A1 CA3174699 A1 CA 3174699A1
Authority
CA
Canada
Prior art keywords
ginsenosides
composition
increasing
gut microbiota
scfas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3174699A
Other languages
English (en)
French (fr)
Inventor
Romain LECOZANNET
Pascale Elizabeth Renee Fanca-Berthon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Givaudan SA
Original Assignee
Givaudan SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2004121.6A external-priority patent/GB202004121D0/en
Priority claimed from GBGB2005288.2A external-priority patent/GB202005288D0/en
Application filed by Givaudan SA filed Critical Givaudan SA
Publication of CA3174699A1 publication Critical patent/CA3174699A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
CA3174699A 2020-03-20 2021-03-17 Ginsenoside compositions Pending CA3174699A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2004121.6A GB202004121D0 (en) 2020-03-20 2020-03-20 Improved compositions
GB2004121.6 2020-03-20
GB2005288.2 2020-04-09
GBGB2005288.2A GB202005288D0 (en) 2020-04-09 2020-04-09 Improved compositions
PCT/EP2021/056803 WO2021185897A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions

Publications (1)

Publication Number Publication Date
CA3174699A1 true CA3174699A1 (en) 2021-09-23

Family

ID=75108332

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3174699A Pending CA3174699A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions
CA3174698A Pending CA3174698A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3174698A Pending CA3174698A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions

Country Status (8)

Country Link
US (2) US20230124503A1 (cg-RX-API-DMAC7.html)
EP (2) EP4121061A1 (cg-RX-API-DMAC7.html)
JP (2) JP7808042B2 (cg-RX-API-DMAC7.html)
CN (2) CN115315264A (cg-RX-API-DMAC7.html)
AU (2) AU2021238639B2 (cg-RX-API-DMAC7.html)
BR (2) BR112022015826A2 (cg-RX-API-DMAC7.html)
CA (2) CA3174699A1 (cg-RX-API-DMAC7.html)
WO (2) WO2021185897A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230124503A1 (en) * 2020-03-20 2023-04-20 Givaudan Sa Ginsenoside compositions
JP2023161983A (ja) * 2022-04-26 2023-11-08 石川県公立大学法人 サポニンを含む酪酸産生菌増殖能向上組成物、腸内常在菌増殖能向上組成物、乳酸菌増殖能向上組成物及びビフィズス菌増殖能向上組成物
CN117224553B (zh) * 2023-11-02 2025-08-12 浙江大学 人参皂苷Rg3在制备治疗或预防肠道病毒感染的药物中的应用
CN117752706B (zh) * 2023-12-20 2025-10-14 浙江天皇药业有限公司 西洋参炮制品在制备治疗甲状腺功能减退症药物中的应用
WO2025261873A1 (en) 2024-06-20 2025-12-26 Givaudan Sa Improvements in or relating to compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202731A1 (en) * 2003-04-08 2004-10-14 Gow Robert T. Rosmarinic acid composition
US20100278944A1 (en) * 2009-05-04 2010-11-04 Naturex, S.A. Application of american ginseng to enhance neurocognitive function
US9956241B2 (en) * 2009-05-04 2018-05-01 Naturex, S.A. Application of American Ginseng to enhance neurocognitive function
KR102200012B1 (ko) * 2013-04-02 2021-01-08 (주)아모레퍼시픽 인삼열매 추출물을 포함하는 뇌 활성화 조성물
US10456436B2 (en) * 2013-11-04 2019-10-29 Wen Luan Wendy Hsiao Use of herbal saponins to regulate gut microflora
BR112020000963A2 (pt) 2017-07-18 2020-07-14 Senescence Life Sciences Pte. Ltd. composições e métodos para o tratamento e prevenção de declínio cognitivo e conservação da função neuronal
CN110613802A (zh) * 2018-06-20 2019-12-27 珠海岐微生物科技有限公司 白茅根大黄炭三七组合物及其在调节肠道微生物中的用途
CN109432304A (zh) * 2018-12-03 2019-03-08 杭州胡庆余堂药业有限公司 一种含铁皮石斛组合物在药物制备中的应用
US20230124503A1 (en) 2020-03-20 2023-04-20 Givaudan Sa Ginsenoside compositions

Also Published As

Publication number Publication date
AU2021238639B2 (en) 2026-06-25
EP4121061A1 (en) 2023-01-25
WO2021185897A1 (en) 2021-09-23
US20230129389A1 (en) 2023-04-27
AU2021238643A1 (en) 2022-10-20
WO2021185890A1 (en) 2021-09-23
US20230124503A1 (en) 2023-04-20
BR112022015826A2 (pt) 2022-10-04
CN115315264A (zh) 2022-11-08
CA3174698A1 (en) 2021-09-23
EP4121076A1 (en) 2023-01-25
BR112022016241A2 (pt) 2022-10-11
JP7850670B2 (ja) 2026-04-23
JP2023518064A (ja) 2023-04-27
JP2023519189A (ja) 2023-05-10
JP7808042B2 (ja) 2026-01-28
CN115315266A (zh) 2022-11-08
AU2021238639A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
US20230124503A1 (en) Ginsenoside compositions
Tian et al. Digestive characteristics of Hericium erinaceus polysaccharides and their positive effects on fecal microbiota of male and female volunteers during in vitro fermentation
Liu et al. Microbiome and metabolome integrally reveal the anti-depression effects of Cistanche deserticola polysaccharides from the perspective of gut homeostasis
Chen et al. Dietary saponins from four popular herbal tea exert prebiotic-like effects on gut microbiota in C57BL/6 mice
CA3161418C (en) Multi-strain probiotic composition and its use
Martirosyan et al. The bioactive compounds of probiotic foods/supplements and their application in managing mental disorders
Campaniello et al. A narrative review on the use of probiotics in several diseases. Evidence and perspectives
WO2022127934A1 (zh) 人参皂苷在改善肠道菌群结构和/或肠屏障功能的应用
JPWO2008155999A1 (ja) Gaba作動性ニューロン賦活剤
US20210121505A1 (en) Compositions and methods for treating inflammatory bowel diseases
JP2022518261A (ja) プレバイオティクス剤として使用するための酵母製品およびそれを含む組成物
Florina et al. The interdependence between diet, microbiome, and human body health-A systemic review
JP7514926B2 (ja) 個別化腸内細菌叢の多様性を整える機能を有する組成物及び使用
JP2011178700A (ja) 錠剤および錠剤製造方法
Lan et al. Protective mechanisms of Hovenia dulcis Thunb extracts on acute alcoholism and liver injury
WO2020049560A1 (en) Methods for supporting weight loss and weight loss maintenance by administration of aquatic plants and/or autologous microbiome samples
Yang et al. The regulatory effects of Lonicera japonica flos on fecal microbiota from humans with type 2 diabetes in a SHIME model
Yang et al. The short-term and long-term effects of Dendrobium officinale leaves polysaccharides on the gut microbiota differ
Li et al. Hemp seed oil ameliorates CFA-induced rheumatoid arthritis in rats by improving metabolic abnormalities and gut microflora
WO2023000408A1 (zh) 包含β-烟酰胺单核苷酸和刺梨提取物的组合物及其应用
TWI810645B (zh) 乳桿菌組合物及其改善抗生素造成之焦慮症的用途
JP7500897B2 (ja) 腸内菌叢改善用組成物
Chi Study on biofate and antidepressive mechanism of fructooligosaccharides from Morinda officinalis
EP3370751B1 (en) Lentil extract with cholesterol lowering and prebiotic activity
JP2024018368A (ja) 腸内細菌叢改善用組成物

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250307

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250307

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250307

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250311

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250313

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250324

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250324

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250324

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250512

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260309

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260309

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260311

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260616

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260625

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260625

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260625